Medistim ASASTU:MD1 -0.99%92 Net Margin % is 19.98% as of Mar. 2026, which is 2% above its 10-year median of 19.59. GuruFocus rates STU:MD1 with a GF Score™ of 92/100 and a GF Value™ of €22.94. The stock has 1 warning sign investors should review. Among 817 Medical Devices & Instruments companies, Medistim ASA ranks better than 90.82% on this metric.
Net margin is calculated as Net Income divided by its Revenue. Medistim ASA's Net Income for the
three
months ended in Mar. 2026 was €3.61 Mil. Medistim ASA's Revenue for the
three
months ended in Mar. 2026 was €18.06 Mil. Therefore, Medistim ASA's net margin for the quarter that ended in Mar. 2026 was 19.98%.
The historical rank and industry rank for Medistim ASA's Net Margin % or its related term are showing as below:
STU:MD1'
s Net Margin % Range Over the Past 10 Years
Min: 14.88 Med: 19.59 Max: 23.44
Current: 21.68
STU:MD1's Net Margin % is ranked better than 90.82% of 817
companies
in the Medical Devices & Instruments industry
Industry Median: 2.09
vs STU:MD1: 21.68
Medistim ASA (STU:MD1) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Medistim ASA Net Margin % Related Terms
Medistim ASA Net Margin % Historical Data
* Premium members only.
The historical data trend for Medistim ASA's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Medistim ASA's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medistim ASA Net Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Medistim ASA's Net Margin % distribution charts can be found below:
* The bar in red indicates where Medistim ASA's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Medistim ASA (STU:MD1) has a Net Margin % of 19.98% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Medistim ASA and its competitors. This is near median its historical median of 19.59. Over the past decade, Medistim ASA's Net Margin % has ranged from 14.88 to 23.44. According to the industry distribution chart, Medistim ASA ranks #75 out of 817 companies in the Medical Devices & Instruments industry, placing it in the top 9.2%.
Is Medistim ASA's Net Margin % too high?
Medistim ASA's current Net Margin % of 19.98% is near median its 10-year median of 19.59. Over the past 10 years, this metric has ranged from a low of 14.88 to a high of 23.44. The Medical Devices & Instruments industry median Net Margin % is 2.09. Medistim ASA's value of 19.98% is 856% above this industry median. Based on the distribution chart, Medistim ASA ranks #75 out of 817 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Medistim ASA has a GF Score™ of 92/100, reflecting its overall financial health beyond just this single metric.
How does Medistim ASA's Net Margin % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Medistim ASA ranks #75 out of 817 companies for Net Margin %. This places Medistim ASA in the top 9% of its industry — outperforming the majority of peers. The industry median Net Margin % is 2.09. Medistim ASA's value of 19.98% is 856% above this benchmark. Historically, Medistim ASA's own Net Margin % has ranged from 14.88 to 23.44 over the past decade. While the company's 10-year median is 19.59 vs. the industry median of 2.09, Medistim ASA has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Medical Devices & Instruments company?
The median Net Margin % among Medical Devices & Instruments companies is 2.09, based on 817 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Medistim ASA's current Net Margin % of 19.98% is 856% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Medistim ASA and its competitors. For the Medical Devices & Instruments industry, the median Net Margin % is 2.09 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medistim ASA's current Net Margin % is 19.98%, which is near median its own 10-year median of 19.59. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medistim ASA stock overvalued right now?
Medistim ASA (STU:MD1) has a current Net Margin % of 19.98%. The stock's GF Value™ is €22.94, compared to a current price of €20.10 — trading 12.4% below its estimated fair value. The current Net Margin % is 19.98%, which is near median its 10-year median of 19.59 and 856% above the Medical Devices & Instruments industry median of 2.09. Medistim ASA's overall GF Score™ is 92/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Medistim ASA (STU:MD1), the current Net Margin % is 19.98% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medistim ASA (STU:MD1) Overvalued in 2026?
Based on GuruFocus' analysis, Medistim ASA stock appears to be undervalued.
The current stock price of €20.10 is trading 12.4% below its estimated GF Value™ of €22.94.
Key valuation signals for STU:MD1:
Net Margin %: 19.98% (near median its 10-year median of 19.59)
GF Value™: €22.94 vs. price of €20.10 (12.4% below fair value)
Industry Position: 856% above the Medical Devices & Instruments median (#75 of 817)
No single metric tells the full story. See the STU:MD1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medistim ASA is a medical device company. It is engaged in researching, developing, producing, distributing, and sales of medical equipment through its own business or participation in other companies, as well as related activities. The company's business is focused on cardiac and vascular surgery. The group operates in the USA, Europe, China, and the Rest of the World. The main divisions are sale of own products and sale of third-party products. Sale of own products has two business models, the capital model and the lease model. Third-party products segment sells medical devices from third party manufacturers in Norway, Sweden and Denmark. Key revenue is generated from Own Products segment.
92GF Score
Get the complete analysis for STU:MD1
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:MD1 has been successfully added to your 
